A retrospective, multicenter study of durvalumab as consolidation therapy in Patients with Locally-Advanced NSCLC after chemoradiotherapy
Latest Information Update: 24 Mar 2022
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Mar 2022 Primary endpoint (progression-free survival) has not been met, according to Results published in the European Journal of Cancer.
- 17 Mar 2022 Status changed from recruiting to completed, according to Results published in the European Journal of Cancer
- 17 Mar 2022 Results published in the European Journal of Cancer